2023
Dynamic changes of circulating soluble PD-1/PD-L1 and its association with patient survival in immune checkpoint blockade-treated melanoma
Lu L, Risch E, Halaban R, Zhen P, Bacchiocchi A, Risch H. Dynamic changes of circulating soluble PD-1/PD-L1 and its association with patient survival in immune checkpoint blockade-treated melanoma. International Immunopharmacology 2023, 118: 110092. PMID: 37004344, DOI: 10.1016/j.intimp.2023.110092.Peer-Reviewed Original ResearchConceptsImmune checkpoint blockadeSoluble PD-L1 (sPD-L1) levelsPD-L1 ratioPD-L1 levelsSoluble PD-1Soluble PD-L1PD-L1PD-1Patient survivalSurvival statusPD-1/PD-L1Immune checkpoints PD-1T cell exhaustionPatients' survival statusSolid tumor typesInitial immunotherapyCheckpoint blockadeMelanoma patientsPoor prognosisRetrospective studyPatient responseCell exhaustionTumor typesMelanomaSurvival
2021
Impact of Neoantigen Expression and T-Cell Activation on Breast Cancer Survival
Li W, Amei A, Bui F, Norouzifar S, Lu L, Wang Z. Impact of Neoantigen Expression and T-Cell Activation on Breast Cancer Survival. Cancers 2021, 13: 2879. PMID: 34207556, PMCID: PMC8228363, DOI: 10.3390/cancers13122879.Peer-Reviewed Original ResearchT cell activationNeoantigen expressionChi-squared testOverall survivalBreast cancerMultivariable Cox proportional hazards modelsMultivariable Cox regression modelsCox proportional hazards modelImproved overall survivalT-cell statusT cell exhaustionBreast cancer patientsKaplan-Meier survivalBreast cancer survivalCox regression modelClinical-pathological variablesReceptor-positive subgroupCancer immunotherapy efficacyProportional hazards modelPearson's chi-squared testTumor-specific somatic mutationsSpearman correlation analysisImmunotherapy efficacyPathological variablesPatient survival